Ascelia Pharma: All eyes on the partner strategy and the FDA process - Redeye

After the recent rights issue, Ascelia has SEK 75.3 in cash before support from warrants, and the company has a runway to end 2025. The Full Study Report for Orviglance is completed, and the next stage is to engage in pre-submission meetings with the FDA on the way to a formal submission by mid-2025. Orviglance continues to feature at conferences, which is important as Ascelia is pursuing a partner strategy for the future launch of Orviglance.

Länk till analysen i sin helhet: https://www.redeye.se/research/1074229/ascelia-pharma-all-eyes-on-the-partner-strategy-and-the-fda-process?utm_source=finwire&utm_medium=RSS